Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models
Abstract Background Eribulin, an inhibitor of microtubule dynamics, shows antitumor potency against a variety of solid cancers through its antivascular activity and remodeling of tumor vasculature. 18F-Fluoromisonidazole (18F-FMISO) is the most widely used PET probe for imaging tumor hypoxia. In thi...
Main Authors: | Songji Zhao, Wenwen Yu, Naoyuki Ukon, Chengbo Tan, Ken-ichi Nishijima, Yoichi Shimizu, Kei Higashikawa, Tohru Shiga, Hiroko Yamashita, Nagara Tamaki, Yuji Kuge |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2019-06-01
|
Series: | EJNMMI Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13550-019-0521-x |
Similar Items
-
Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
by: Shinichiro Kashiwagi, et al.
Published: (2018-03-01) -
Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors
by: Yoichi Shimizu, et al.
Published: (2021-01-01) -
Multivariate Regularized Newton and Levenberg-Marquardt methods: a comparison on synthetic data of tumor hypoxia in a kinetic framework
by: Garbarino Sara, et al.
Published: (2019-01-01) -
The Roles of Hypoxia Imaging Using <sup>18</sup>F-Fluoromisonidazole Positron Emission Tomography in Glioma Treatment
by: Kenji Hirata, et al.
Published: (2019-07-01) -
First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer
by: Sébastien Thureau, et al.
Published: (2021-08-01)